Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13267555 | 1.00 | LMNA (0.53) | LMNATP53HTTRAB9AMEN1 | |
| SCHEMBL13137656 | 0.86 | LMNA (0.50) | LMNATP53HTTRAB9AMEN1 | |
| SCHEMBL24762848 | 0.83 | LMNA (0.47) | LMNATP53HTTRAB9AMEN1 | |
| SCHEMBL8210156 | 0.80 | LMNA (0.67) | LMNATP53HTTRAB9AMEN1 | |
| SCHEMBL8298242 | 0.79 | LMNA (0.59) | LMNATP53HTTRAB9AMEN1 | |
| SCHEMBL19965517 | 0.79 | LMNA (0.59) | LMNATP53HTTRAB9AMEN1 | |
| SCHEMBL8353840 | 0.79 | LMNA (0.59) | LMNATP53HTTRAB9AMEN1 | |
| SCHEMBL8196834 | 0.78 | MEN1 (0.52) | LMNATP53HTTRAB9AMEN1 | |
| SCHEMBL5270032 | 0.78 | POLB (0.54) | LMNATP53HTTRAB9AMEN1 | |
| SCHEMBL5272037 | 0.78 | POLB (0.54) | LMNATP53HTTRAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291902-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291902-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | PRSS1, SERPINB1, SPINT2 | LMNA 1443/4885TP53 552/4885HTT 3219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.